Health Canada Proposes Streamlined Drug Approvals Through Foreign Regulatory Partnerships
Key Insights
Health Canada has published a draft ministerial order proposing to accelerate drug approvals by relying on decisions from trusted foreign regulators, though specific regulators have not yet been named.
The initiative responds to industry complaints about slow approval times, particularly for generic drugs (search) which saw a 43% increase in applications since 2016.
Critics express concerns about potential reduction in Health Canada's due diligence and worry about including the FDA given recent upheavals under the Trump administration.
Health Canada has unveiled plans to accelerate pharmaceutical approvals by leveraging regulatory decisions from trusted foreign authorities, marking a significant shift in the country's drug review process. The draft ministerial order, published before the holidays, outlines proposals to quicken drug approvals by relying on work already completed by international regulators, though the specific trusted authorities have not yet been identified.
Three-Pronged Approach to Regulatory Collaboration
The draft order proposes three distinct pathways for international regulatory cooperation. Health Canada could deem parts of a drugmaker's submission as already completed if the drug has been approved by a trusted foreign regulator. Alternatively, the agency could draw on elements of in-progress reviews by another drug authority, provided companies file in Canada within 120 days of applying to the other regulator. The third option involves conducting more joint reviews with foreign regulators.
André Gagnon, a Health Canada spokesman, stated that "Health Canada will make decisions on which regulatory authorities it can rely on based on established partnerships and comparable regulatory standards. The department will also be able to modify the list of trusted regulatory authorities as appropriate."
Addressing Industry Concerns Over Approval Delays
The initiative directly responds to mounting criticism from the pharmaceutical industry and patients regarding Health Canada's approval timelines. The problem is particularly acute for generic drugs (search), with fewer generic approval rulings completed on time in 2024 compared to 2023. Health Canada has faced a 43% increase in new generic drug applications since 2016, contributing to processing delays.
The draft order identifies three potential drug classes for initial implementation: drugs for pets, drugs for food-producing animals, and drugs authorized for children, including pediatric formulations. The Canadian Generic Pharmaceutical Association (search) has urged Health Canada to prioritize timely reviews of cheaper generics to help lower medication costs for patients.
International Precedents and Expert Concerns
Several peer countries, including Australia, Switzerland, Britain, and Singapore, already have approval pathways that rely to some degree on foreign regulatory decisions. However, experts have raised concerns about potential risks to Canada's regulatory independence.
Matthew Herder, director of the Health Law Institute at Dalhousie University, expressed particular concern about including the current FDA on the trusted regulators list. "If you look at decisions by the EMA versus FDA versus Health Canada, you actually see a lot of nuance," Herder noted. "And in a time as volatile as we're living in, I actually think you want redundancies in the system, not one gatekeeper effectively, which is what this could lead to."
The Trump administration has cut thousands of jobs at the FDA and installed leaders skeptical of vaccines, raising questions about the agency's current reliability as a regulatory partner.
Broader Context of Drug Access Challenges
While the proposal addresses approval timelines, experts note that regulatory approval represents only part of Canada's drug access challenge. On average, it takes a drug two-and-a-half years to progress from approval to public reimbursement—the longest wait in the G7.
Adam Houston, an adjunct professor of health law at the University of Ottawa, hopes the streamlined process will encourage pharmaceutical companies to apply for Canadian approval of child-friendly drug formulations authorized elsewhere, such as tuberculosis (search) medications. "Health Canada is pretty good at being the bouncer at the nightclub," Houston observed, "in that it keeps out drugs that are unsafe or ineffective. But if there's something really good that we want to have, they can't drag you inside."
Industry Response and Next Steps
Innovative Medicines Canada (search), representing brand-name drug makers, has expressed general support for efforts to make Health Canada's approval process faster and more efficient. The Canadian Veterinary Medical Association (search) said it was "encouraged" by the draft order, having lobbied for Health Canada to collaborate with foreign regulators to address drug shortages.
A public consultation period runs until February 28, during which stakeholders will provide input on the proposed changes. The pharmaceutical industry and regulatory experts are closely watching to see which foreign regulators and drug categories Health Canada will include in its initial implementation.